Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Figure 4 Kaplan-Meier plot of overall survival at baseline.
A: Kaplan-Meier plot of overall survival (OS) at baseline (neutrophil-to-lymphocyte ratio < 2.43 vs > 2.43); B: Kaplan-Meier plot of OS at baseline (platelet-to-lymphocyte ratio < 139.7 vs > 139.7); C: Kaplan-Meier plot of OS at baseline [neutrophil-to-(leukocyte-neutrophil) ratio < 1.72 vs > 1.72]. OS: Overall survival; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; dNLR: Neutrophil-to-(leukocyte-neutrophil) ratio; CI: Confidence interval; HR: Hazard ratio.
- Citation: Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5641